STAT Plus: Startup Arkuda targets rapidly advancing, rare form of dementia
A rare inherited form of early-onset dementia that typically strikes people between the ages of 45 and 65 is the focus of a new biotech startup that officially launched Thursday.
Arkuda Therapeutics of Cambridge, Mass., has been incubated by Atlas Venture since February of last year. It has $44 million in venture capital raised by Atlas and the venture capital arm of Pfizer, the pharmaceutical giant.
Continue to STAT Plus to read the full story…
Read Original Article: STAT Plus: Startup Arkuda targets rapidly advancing, rare form of dementia »